Fabry Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Buy Report

Published: April 29, 2022 Report Code: GMDGDHC22122IDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures
FAQs

Fabry Disease Pipeline Drugs Market Overview

Fabry Disease Drugs pipeline drugs market research report provides comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects.

Key Targets in the Fabry Disease Pipeline Drugs Market

The key targets in the Fabry Disease pipeline drugs market are Alpha Galactosidase A, Ceramide Glucosyltransferase, Bromodomain Containing Protein 4, and Interleukin 1 Receptor. Alpha Galactosidase A has the highest pipeline products.

Fabry Disease Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Fabry Disease Drugs Pipeline Market

The key MoA in the Fabry Disease Drugs pipeline market are Alpha Galactosidase A Replacement, Alpha Galactosidase A Activator, Ceramide Glucosyltransferase Inhibitor, Bromodomain Containing Protein 4 Inhibitor, and Interleukin 1 Receptor Antagonist. Alpha Galactosidase A Replacement has the highest pipeline products.

Fabry Disease Drugs Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Fabry Disease Pipeline Drugs Market

The key RoA in the Fabry Disease pipeline drugs market are intravenous, oral, and subcutaneous. Intravenous has the highest pipeline products.

Fabry Disease Pipeline Drugs Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Fabry Disease Drugs Pipeline Market

The key molecule types in the Fabry Disease Drugs pipeline market are gene therapy, recombinant enzyme, small molecule, gene-modified cell therapy, biologic, enzyme, fusion protein, and recombinant protein. Gene therapy has the highest pipeline products.

Fabry Disease Drugs Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Fabry Disease Drugs Pipeline Market

The key companies in the Fabry Disease Drugs pipeline market are Chiesi Farmaceutici SpA, M6P Therapeutics, Takeda Pharmaceutical Co Ltd, Yuhan Corp, 4D Molecular Therapeutics Inc, AceLink Therapeutics Inc, and CANbridge Life Sciences Ltd. Chiesi Farmaceutici SpA has the highest pipeline products.

Fabry Disease Drugs Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets	Alpha Galactosidase A, Ceramide Glucosyltransferase, Bromodomain Containing Protein 4, and Interleukin 1 Receptor
Key MoA	Alpha Galactosidase A Replacement, Alpha Galactosidase A Activator, Ceramide Glucosyltransferase Inhibitor, Bromodomain Containing Protein 4 Inhibitor, and Interleukin 1 Receptor Antagonist
Key RoA	Intravenous, Oral, and Subcutaneous
Key molecule Types	Gene Therapy, Recombinant Enzyme, Small Molecule, Gene-Modified Cell Therapy, Biologic, Enzyme, Fusion Protein, and Recombinant Protein
Key companies	Chiesi Farmaceutici SpA, M6P Therapeutics, Takeda Pharmaceutical Co Ltd, Yuhan Corp, 4D Molecular Therapeutics Inc, AceLink Therapeutics Inc, and CANbridge Life Sciences Ltd

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Fabry Disease (Genetic Disorders).
The pipeline guide reviews pipeline therapeutics for Fabry Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Fabry Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Fabry Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Fabry Disease (Genetic Disorders)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fabry Disease (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fabry Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

4D Molecular Therapeutics Inc
AceLink Therapeutics Inc
Amicus Therapeutics Inc
Bioasis Technologies Inc
Biosidus SA
CANbridge Life Sciences Ltd
CellGenTech Inc
Chiesi Farmaceutici SpA
Equaly SA
Freeline Therapeutics Holdings Plc
GC Pharma
Hanmi Pharmaceuticals Co Ltd
Idorsia Pharmaceutical Ltd
M6P Therapeutics
Pharming Group NV
Resverlogix Corp
Sangamo Therapeutics Inc
Sanofi
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
UniQure NV
Yuhan Corp

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Fabry Disease – Overview

Fabry Disease – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fabry Disease – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fabry Disease – Companies Involved in Therapeutics Development

Fabry Disease – Drug Profiles

Fabry Disease – Dormant Projects

Fabry Disease – Discontinued Products

Fabry Disease – Product Development Milestones

Table

List of Tables

Number of Products under Development for Fabry Disease, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Fabry Disease – Pipeline by 4D Molecular Therapeutics Inc, 2022

Fabry Disease – Pipeline by AceLink Therapeutics Inc, 2022

Fabry Disease – Pipeline by Amicus Therapeutics Inc, 2022

Fabry Disease – Pipeline by Bioasis Technologies Inc, 2022

Fabry Disease – Pipeline by Biosidus SA, 2022

Fabry Disease – Pipeline by CANbridge Life Sciences Ltd, 2022

Fabry Disease – Pipeline by CellGenTech Inc, 2022

Fabry Disease – Pipeline by Chiesi Farmaceutici SpA, 2022

Fabry Disease – Pipeline by Equaly SA, 2022

Fabry Disease – Pipeline by Freeline Therapeutics Holdings Plc, 2022

Fabry Disease – Pipeline by GC Pharma, 2022

Fabry Disease – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022

Fabry Disease – Pipeline by Idorsia Pharmaceutical Ltd, 2022

Fabry Disease – Pipeline by M6P Therapeutics, 2022

Fabry Disease – Pipeline by Pharming Group NV, 2022

Fabry Disease – Pipeline by Resverlogix Corp, 2022

Fabry Disease – Pipeline by Sangamo Therapeutics Inc, 2022

Fabry Disease – Pipeline by Sanofi, 2022

Fabry Disease – Pipeline by Sigilon Therapeutics Inc, 2022

Fabry Disease – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Fabry Disease – Pipeline by UniQure NV, 2022

Fabry Disease – Pipeline by Yuhan Corp, 2022

Fabry Disease – Dormant Projects, 2022

Fabry Disease – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Fabry Disease, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

What are the key targets in the Fabry Disease Drugs pipeline market?

The key targets in the Fabry Disease Drugs pipeline market are Alpha Galactosidase A, Ceramide Glucosyltransferase, Bromodomain Containing Protein 4, and Interleukin 1 Receptor. Alpha Galactosidase A has the highest pipeline products.
What are the key MoA in the Fabry Disease Drugs pipeline market?

The key MoA in the Fabry Disease Drugs pipeline market are Alpha Galactosidase A Replacement, Alpha Galactosidase A Activator, Ceramide Glucosyltransferase Inhibitor, Bromodomain Containing Protein 4 Inhibitor, and Interleukin 1 Receptor Antagonist.
What are the key RoA in the Fabry Disease Drugs pipeline market?

The key RoA in the Fabry Disease Drugs pipeline market are intravenous, oral, and subcutaneous.
What are the key molecule types in the Fabry Disease Drugs pipeline market?

The key molecule types in the Fabry Disease Drugs pipeline market are gene therapy, recombinant enzyme, small molecule, gene-modified cell therapy, biologic, enzyme, fusion protein, and recombinant protein.
What are the key companies in the Fabry Disease Drugs pipeline market?

The key companies in the Fabry Disease Drugs pipeline market are Chiesi Farmaceutici SpA, M6P Therapeutics, Takeda Pharmaceutical Co Ltd, Yuhan Corp, 4D Molecular Therapeutics Inc, AceLink Therapeutics Inc, and CANbridge Life Sciences Ltd.

Fabry Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports

Currency USD

Single User

$2,000

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Genetic Disorders reports

Pharmaceuticals

New

New Drug Approvals and Their Contract Manufacture - 2024 Edition

Pharmaceuticals

New

Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033

Pharmaceuticals

New

Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Fabry Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

Access a live Fabry Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Fabry Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fabry Disease Pipeline Drugs Market Overview

Key Targets in the Fabry Disease Pipeline Drugs Market

Key MoA in the Fabry Disease Drugs Pipeline Market

Key RoA in the Fabry Disease Pipeline Drugs Market

Key Molecule Types in the Fabry Disease Drugs Pipeline Market

Key Companies in the Fabry Disease Drugs Pipeline Market

Market report overview

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports